Matt earned his PhD from Yale University in 2019. He joined the lab of Dr. Justin Kim where he aims to develop a platform for the discovery of macrocyclic peptide therapeutics. Macrocyclic peptides offer properties that bring to bear several key benefits of other therapeutic modalities. Similarly to small molecules, macrocyclic peptides can be optimized for cell-permeability and oral bioavailability, and similarly to antibody-based therapeutics, they can adhere to relatively flat and featureless protein surfaces. In combination, these properties make macrocyclic peptides ideal for therapeutic targets that are often recalcitrant to small-molecule- and antibody-based therapeutics, such as intracellular protein-protein interactions. Matt will begin construction of peptidic libraries containing homodetic peptides and move toward incorporation of synthetic, natural-product-inspired building blocks. With this large pool of amino acids, the generated libraries will achieve rapid structural diversity that is unparalleled within currently available peptide discovery platforms and should aid in achieving therapeutic endpoints. Matt joined the CCBM T32 training program to learn as much as he can during his time at DFCI while being a part of a great community of scholars.